Renal Biomarkers Market Report 2025

This Renal Biomarkers report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The renal biomarkers market size has grown strongly in recent years. It will grow from $1.28 billion in 2024 to $1.38 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increasing prevalence of kidney diseases, advances in medical diagnostics, aging population, growing awareness of early disease detection, adoption of point-of-care testing, rise in chronic diseases.

The renal biomarkers market size is expected to see strong growth in the next few years. It will grow to $1.91 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to personalized medicine and targetedTherapies, integration of biomarker testing into routine clinical practice, emerging markets in asia and latin america, non-invasive biomarker testing methods, continuous monitoring with wearable devices. Major trends in the forecast period include multiplex biomarker panels for comprehensive disease profiling, ai and machine learning for biomarker discovery, biomarker-based companion diagnostics, poc biomarker testing in home healthcare settings, biomarkers for early detection and prevention.

The increase in geriatric and pediatric renal patients is expected to drive the growth of the renal biomarkers market in the coming years. Geriatric renal patients refer to elderly individuals over the age of 70 with advanced chronic kidney disease (CKD), while pediatric renal patients are those diagnosed with renal disorders during childhood and young adulthood. Renal biomarkers are essential for assessing the severity of kidney injury in both geriatric and pediatric patients. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency, reported that chronic kidney disease (CKD) mortality rates rose by 4.2% in 2021 and 6.2% in 2022. Thus, the increasing number of geriatric and pediatric renal patients is contributing to the growth of the renal biomarkers market.

The increasing incidence of chronic kidney diseases is expected to drive the growth of the renal biomarkers market in the future. Chronic kidney disease (CKD) is a condition marked by the gradual decline in kidney function over time. Renal biomarkers are essential for detecting and monitoring the progression of CKD, enabling timely interventions and personalized treatment strategies, which lead to better patient outcomes. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency, reported that CKD mortality rates rose by 4.2% in 2021 and 6.2% in 2022. As a result, the growing prevalence of chronic kidney diseases is fueling the expansion of the renal biomarkers market.

Technological advancements have become a key trend gaining traction in the renal biomarkers market. Leading companies in the sector are focusing on developing innovative technologies to maintain their market position. For example, in March 2022, Nipro Medical Corporation, a US-based medical equipment manufacturer, introduced the SURDIAL DX. This advanced hemodialysis system incorporates cutting-edge technology to ensure optimal patient safety, comfort, and efficiency. It features modern design elements such as streamlined automated processes, ergonomic design, and a focus on improving the overall dialysis treatment experience.

Strategic collaborations and partnerships with start-ups and mid-sized companies are becoming increasingly prevalent in the renal biomarkers market. This approach allows major companies to expand their product and service offerings. In June 2022, Nordic Bioscience, a Denmark-based biomarker company, strengthened its collaboration with F. Hoffmann-La Roche Ltd., a multinational healthcare company. This collaboration involves the development of proprietary biomarkers related to tissue breakdown and build-up. Nordic Bioscience's ECM biomarkers are deemed essential for various chronic diseases, including kidney diseases. The partnership aims to improve clinical decisions in drug development and patient selection, ultimately enhancing patient outcomes.

In January 2024, Novartis AG, a Switzerland-based pharmaceutical company, acquired SanReno Therapeutics for an undisclosed amount. This rare acquisition of a Chinese biotech firm by a multinational company underscores China's potential in the global renal market and aligns with Novartis' commitment to innovative therapies for kidney diseases. SanReno Therapeutics is a China-based biopharmaceutical company that specializes in renal disease therapies.

Major companies operating in the renal biomarkers market include Abbott Laboratories, BioPorto Diagnostics A/S, Roche Holding AG, Thermo Fisher Scientific, bioMérieux SA, Randox Laboratories, Siemens Healthineers, Beckman Coulter Inc., Astute Medical Inc., Nexelis Company, Sphingotec GmbH, Bio-Rad Laboratories India Pvt. Ltd., Enzo Biochem Inc., PerkinElmer Inc., Novartis AG, Alere Inc., AstraZeneca plc, Bio-Techne Corp., DiaSorin S.p.A., EKF Diagnostics Holdings plc, Fujirebio Diagnostics Inc., Gold Standard Diagnostics Corp., Merck KGaA, Myriad RBM Inc., Ortho Clinical Diagnostics Holdings plc, Quidel Corporation, R&D Systems Inc., Roche Diagnostics International Ltd., Sekisui Chemical Co. Ltd., Sysmex Corporation, Tosoh Bioscience Inc.

North America was the largest region in the renal biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The regions covered in the renal biomarkers market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the renal biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Renal biomarkers encompass proteins, lipids, genes, metabolites, proteomic patterns, or cells that are identified through urinalysis to assess the glomerular filtration rate of the kidney. A decrease in this rate is indicative of kidney damage, and renal biomarkers are instrumental in estimating the nature and severity of such injuries.

The main types of biomarkers in renal biomarker analysis include functional biomarkers, upregulated proteins, and other biomarker categories. Functional biomarkers are particularly significant as they allow the diagnosis of kidney injury in individuals with normal kidney function and in chronic kidney disease patients where the same injury would result in a substantial decrease in functional biomarkers like creatinine (Cr). Various diagnostic techniques, such as enzyme-linked immunosorbent assay, particle-enhanced turbidimetric immunoassay (PETIA), colorimetric assay, chemiluminescent enzyme immunoassay (CLIA), and liquid chromatography-mass spectrometry (LC-MS), are employed for renal biomarker analysis. These biomarkers find applications in diagnosis, disease progression monitoring, and research, and they are utilized by hospitals, diagnostic laboratories, and other end-users.

The renal biomarker market research report is one of a series of new reports that provides renal biomarker market statistics, including renal biomarker industry global market size, regional shares, competitors with a renal biomarker market share, detailed renal biomarker market segments, market trends and opportunities, and any further data you may need to thrive in the renal biomarker industry. This renal biomarker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The renal biomarker market consists of revenues earned by entities by providing renal biomarker services such as integrated drug discovery, phenotypic assay, custom services, in vivo, biomarker identification, glomerular filtration diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The renal biomarker market also includes sales of point-of-care kit, antibody screening, cell-based diagnostic devices which are used in providing renal biomarker services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.